Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Integrated DNA Technologies
Integrated DNA Technologies sells short strands of DNA called oligonucleotides, which are used by researchers as research tools.
Sector
Subsector
Keywords
Location
total rounds
Arrayit
Arrayit manufactures proprietary technologies and consumables for disease prevention, treatment, and cure.
Sector
Subsector
Location
total rounds
total raised
BUGS Bioscience
BUGS Bioscience is a global centre of excellence for pathogen microarrays and genomics, supporting a collaborative network of researchers.
Sector
Subsector
Keywords
Location
Lucigen
Lucigen is a life science research company that provides solutions for DNA cloning, sequencing, amplification, and protein expression.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds11
Number of Funding Rounds
Money Raised
Their latest funding was raised on 17.08.2023. Their latest round Post-IPO Equity
Co-Investors
Investors12
Number of lead investors
Number of investors
Monsanto
Monsanto Company, now part of Bayer, is a multinational corporation that provides agricultural products for farmers around the world.
Sector
Subsector
Location
count Of Investments
count Of Exists
Mohr Davidow Ventures
Mohr Davidow Ventures invests in early-stage technology startups to create new markets.
Sector
Subsector
Location
count Of Investments
count Of Exists
Sue Siegel
Sue Siegel brings 25 years experience commercializing key enabling technologies in biomedical research and healthcare. She leads investments in personalized medicine spanning areas that include technology platforms to molecular diagnostics to online healthcare, all of which leverage the power of cross-disciplinary convergence. She partners with entrepreneurs that offer "disruptive innovation" business solutions to pressing healthcare challenges: age-onset and lifestyle-induced health conditions, consumer-driven wellness preservation, and those that improve healthcare economics. Prior to joining MDV, Sue was President and Director of Affymetrix, Inc., a company that pioneered GeneChip®technology and was instrumental in the expansion of genomics-based personalized medicine. During her tenure, she grew Affymetrix to become a multibillion dollar market cap company. At Amersham International (now GE), she held several senior executive roles, including President of Hoefer-Pharmacia Biotech. At Amersham, Sue played a key role in growing businesses through acquisitions and via the commercialization of novel enabling technologies. She was also involved in commercializing key biomedical technologies at E. I. DuPont & Co., Eastman Kodak Co., and Bio-Rad Laboratories. Sue serves on the board of The Tech Museum of Innovation, is a member of the Presidents' Circle of the National Academies, and serves as an advisor to the Institute of Medicine. As Chair of the Community Relations Committee of The Gladstone Institute in San Francisco, she leads the effort to expand this leading biomedical research organization to the global community. Sue was elected as a Henry Crown Fellow of the Aspen Institute in 2003. As part of this Fellowship, she co-founded at the Stanford Hospital Geriatric Department, Checking-In™, an organization dedicated to serving our aging population. She is a Council member for the Institute for Immunity, Transplantation, and Infectious Diseases (ITI) at Stanford Medical School and is an Officer of the Golden Gate Chapter of YPO. Sue has served as a Regional Panelist for the selection of White House Fellows, on the Council on Biotechnology Research, Innovation, and Public Policy for the Center for Strategic and International Studies (CSIS), and on the IBM Life Sciences and Healthcare Strategic Advisory Council. Sue received a M.S. in Biochemistry and Molecular Biology from Boston University Medical School where she studied cellular differentiation in mouse embryonic carcinoma stem cells. She received her B.S. in Biology from the University of Puerto Rico.
current job
Kleiner Perkins
Kleiner Perkins is a venture capital firm that invests in early-stage, incubation and growth companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Brook Byers
Brook Byers is the Board Director of Foundation Medicine Inc. He has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook was the founding President and then Chairman, of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of nine companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, Pacific Biosciences, Inc., Tethys, XDx, Inc He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Hybritech (Chairman), Genprobe and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, molecular diagnostics and genomics. Brook was President and a Director of the Western Association of Venture Capitalists. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford Bio-X Advisory Council and the Stanford Eye Council. He was Co - Chair of the five year, $1.4 billion, UCSF Capital Campaign. In 2007, he was awarded the UCSF Medal as their honorary degree equivalent. He was formerly a Director of the Entrepreneurs Foundation, the California Healthcare Institute, the Asian Art Museum in San Francisco, the Stanford Graduate School of Business Advisory Council, That Many May See (UCSF) Vision Research Foundation (Chairman) and the Georgia Tech Advisory Board. Raised in Atlanta, Georgia, Brook graduated in Electrical Engineering from Georgia Tech. He received an MBA from Stanford.
current job
count Of Investments
Acquisitions3
Apton Biosystems acquired by Pacific Biosciences
acquirer
date
type
price
Apton Biosystems
Apton Biosystems develops Super-Res sequencing and single-molecule protein detection systems.
Sector
Subsector
Location
total rounds
total raised
Circulomics acquired by Pacific Biosciences
acquirer
date
type
Circulomics
Circulomics streamlines genomics research and clinical diagnostics using micro- and nanotechnologies.
Sector
Subsector
Location
total rounds
total raised
Omniome acquired by Pacific Biosciences
acquirer
date
type
price
Omniome
Omniome develops a proprietary DNA sequencing platform with unsurpassed accuracy.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders2
Joseph Bonventre
Joseph Bonventre is Samuel A. Levine Professor of Medicine Harvard Medical School. He is also Chief of the Renal Division of the Brigham and Women’s Hospital (BWH), Chief of the BioMedical Engineering Division at the BWH, and former Associate Director and then Co-Director of the Harvard-MIT Division of Health Sciences and Technology. Joseph Bonventre is Past-President of the American Society of Nephrology. Joseph Bonventre received his BS with distinction from Cornell in 1970 in Engineering Physics and MD and Ph.D. degrees in Biophysics from Harvard University in 1976 and 1979, respectively. He has honorary doctorate degrees from Mt. Saint Mary’s College and from the Norwegian Institute of Science and Technology in Norway. His research focuses primarily on the study of kidney injury and repair, with special emphasis on the role of biomarkers, inflammation and stem cells. Joseph Bonventre has received two MERIT awards from the National Institutes of Diabetes and Digestive Disorders. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the American Institute for Medical and Biological Engineering. He is editor of Seminars in Nephrology. He serves as an advisor to many academic institutions, pharmaceutical companies and biotechnology companies. He is co-founder of Patientkeeper, Inc and Pacific Biosciences Inc. Joseph Bonventre is past-president of the Massachusetts, Rhode Island, New Hampshire and Vermont affiliate and has received that chapter’s Outstanding Physician Award. He is a founder and member of the Board of Directors of the National Space Biology Research Institute and is an Emeritus member of the Board of Advisors of the Dean, School of Engineering of Cornell University.
current job
organization founded
Joseph Bonventre
Stephen Turner
Dr. Turner founded Pacific Biosciences (formerly Nanofluidics) and secured its Series A funding in 2004. He was awarded a Ph.D. in Physics by Cornell University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures. His work contributed to the establishment of the Nanotechnology Center at Cornell. He was a member of the project team at Cornell which developed the technology now employed by Pacific Biosciences and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. Dr. Turner's undergraduate work was at the University of Wisconsin, Madison, where he received a Bachelor of Science in Applied Mathematics, Electrical Engineering and Physics. He is the author of over 30 scientific papers in fields ranging from nanofluidics, genetics, cell attachment to chemically- and topographically- modified surfaces, x-ray lithography and process modeling. He is listed as the inventor on nine U.S. patents and more than 20 published patent applications. Dr. Turner was recipient of the MIT Technology Review "TR100" Award in 2003 and the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008. He is a sitting member of the National Institutes of Health grant review study section on new technologies. He oversees the scientific and technical direction of Pacific Biosciences.
current job
organization founded
Stephen Turner
Employee Profiles160
Helena Kuftinec
Marketing specialist, strategic marketing
Arghavan Arjmand
Staff photonic chip design engineer
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range